Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)

v3.19.3.a.u2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)
Total
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Stockholders Deficit Trans Biotec Inc [Member]
Noncontrolling Interest [Member]
Balance, shares at Dec. 31, 2017 109,409,930 1,388,575
Balance, amount at Dec. 31, 2017 $ (2,964,137) $ 1,096 $ 14 $ 14,785,051 $ (17,703,171) $ (2,917,010) $ (47,127)
Net loss for the period (143,870)     $ (143,049) (143,049) $ (821)
Paid-in capital - gain on related party debt conversion 7,776   7,776   7,776  
Common stock issued for services, shares            
Paid-in capital - relative fair value of stock warrants granted 10,958   10,958   10,958  
Common stock issued to settle accounts payable, shares   91,148          
Common stock issued to settle accounts payable, amount $ 428 $ 1   $ 427   $ 428  
Balance, shares at Mar. 31, 2018 109,501,078 1,388,575
Balance, amount at Mar. 31, 2018 $ (3,088,845) $ 1,097 $ 14 $ 14,804,212 $ (17,846,220) $ (3,040,897) $ (47,948)
Net loss for the period (151,614) $ (150,810) (150,810) $ (804)
Paid-in capital - gain on related party debt conversion $ 7,367   7,367   $ 7,367  
Common stock issued for services, shares 6,000,000        
Paid-in capital - relative fair value of stock warrants granted $ 18,743   18,743   $ 18,743  
Paid-in capital - beneficial conversion feature 6,000   6,000   6,000  
Common stock issued due to options exercise, amount 4,500 5   4,495   4,500  
Common stock issued for compensation, amount 8,000 $ 9   7,991   8,000  
Common stock issued due to options exercise, shares   450,000          
Common stock issued for compensation, shares   800,000          
Common stock issued for services, amount $ 25,800 $ 61   $ 25,739   $ 25,800  
Balance, shares at Jun. 30, 2018 116,751,078 1,388,575
Balance, amount at Jun. 30, 2018 $ (3,170,049) $ 1,172 $ 14 $ 14,874,547 $ (17,997,030) $ (3,121,297) $ (48,752)
Balance, shares at Dec. 31, 2018 116,751,078 1,388,575
Balance, amount at Dec. 31, 2018 $ (3,423,431) $ 1,172 $ 14 $ 14,887,804 $ (18,262,804) $ (3,373,146) $ (50,285)
Net loss for the period (139,056)     $ (138,289) (138,289) $ (767)
Paid-in capital - gain on related party debt conversion 8,113   8,113   8,113  
Paid-in capital - relative fair value of stock warrants granted 22,665   22,665   22,665  
Common stock issued for cash, shares   35,454,547          
Common stock issued for cash, amount $ 39,000 $ 350   $ 38,650   $ 39,000  
Balance, shares at Mar. 31, 2019 152,205,625 1,388,575
Balance, amount at Mar. 31, 2019 $ (3,492,709) $ 1,522 $ 14 $ 14,957,232 $ (18,400,425) $ (3,441,657) $ (51,052)
Net loss for the period (156,955) $ (156,137) (156,137) $ (818)
Paid-in capital - gain on related party debt conversion 7,409   7,409   7,409  
Paid-in capital - relative fair value of stock warrants granted $ 12,365   $ 12,365   $ 12,365  
Balance, shares at Jun. 30, 2019 152,205,625 1,388,575
Balance, amount at Jun. 30, 2019 $ (3,629,890) $ 1,522 $ 14 $ 14,977,006 $ (18,556,562) $ (3,578,020) $ (51,870)